Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV
复制标题
DOI：
10.26355/eurrev_202002_20379
复制
发表时间：
2020-02-01
影响因子：
3.3
通讯作者：
Ahmed, N.
中科院分区：
文献类型：
--
作者：
Meo, S. A.;Alhowikan, A. M.;Ahmed, N.
目的：人畜共患冠状病毒的人类感染具有新出现和再出现的致病特征，引起了极大的公共卫生关注。本研究旨在调查中国武汉新型冠状病毒（2019-nCoV）、严重急性呼吸综合征冠状病毒（SARS-CoV）的全球流行情况、生物学和临床特征。材料与方法：“2019-nCoV、SARS-CoV和MERS-CoV”全球疫情资料来源于世界卫生组织（WHO）、美国疾病控制和预防中心（CDC）、相关部委和研究机构。我们还记录了ISI Web of Science和研究中心在全球科学期刊上发表的关于2019-nCoV、SARS-CoV和MERS-CoV的流行率、生物学和临床特征的研究文献信息。从2002年11月至2003年8月，SARS冠状病毒在全球范围内涉及32个国家，共有8422例确诊病例和916例（10.87%）伤亡。MERS-CoV在27个州蔓延，在2012年4月至2019年12月期间造成2496例病例和868例（34.77%）死亡。然而，新型冠状病毒2019-nCoV迅速蔓延到27个国家的全球边境。在2019年12月29日至2月7日期间，它感染了34799人，造成724人（2.08%）伤亡。2020. MERS-CoV的病死率（34.77%）高于SARS-CoV（10.87%）和2019-nCoV（2.08%）;但与SARS-CoV和MERS-CoV相比，2019-nCoV传播迅速。结论：新型冠状病毒2019-nCoV具有多样的流行病学和生物学特征，使其比SARS-CoV和MERS-CoV更具传染性。与SARS-CoV和MERS-CoV相比，它在短时间内影响了更多的人，尽管MERS-CoV的致死率高于SARS-CoV和2019-nCoV。冠状病毒感染2019-nCoV，MERS-CoV和SARS CoV的主要临床表现是发热，寒战。咳嗽.呼吸短促、全身性肌痛、不适、嗜睡、腹泻、意识模糊、呼吸困难和肺炎。全球卫生当局应立即采取措施，防止这种新出现和重新出现的病原体在地球仪各地爆发，以尽量减少地方和全球的疾病负担。
OBJECTIVE: Human infections with zoonotic coronavirus contain emerging and reemerging pathogenic characteristics which have raised great public health concern. This study aimed at investigating the global prevalence, biological and clinical characteristics of novel coronavirus, Wuhan China (2019-nCoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection outbreaks.MATERIALS AND METHODS: The data on the global outbreak of "2019-nCoV, SARS-CoV, and MERS-CoV" were obtained from World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), concerned ministries and research institutes. We also recorded the information from research documents published in global scientific journals indexed in ISI Web of Science and research centers on the prevalence, biological and clinical characteristics of 2019-nCoV, SARS-CoV, and MERS-CoV.RESULTS: Worldwide, SARS-CoV involved 32 countries, with 8422 confirmed cases and 916 (10.87%) casualties from November 2002 to August 2003. MERS-CoV spread over 27 states, causing 2496 cases and 868 (34.77%) fatalities during the period April 2012 to December 2019. However, the novel coronavirus 2019-nCoV spread swiftly the global borders of 27 countries. It infected 34799 people and resulted in 724 (2.08%) casualties during the period December 29, 2019 to February 7. 2020. The fatality rate of coronavirus MERS-CoV was (34.77%) higher than SARS-CoV (10.87%) and 2019-nCoV (2.08%); however, the 2019-nCoV transmitted rapidly in comparison to SARS-CoV and MERS-CoV.CONCLUSIONS: The novel coronavirus 2019-nCoV has diverse epidemiological and biological characteristics, making it more contagious than SARS-CoV and MERS-CoV. It has affected more people in a short time period compared to SARS-CoV and MERS-CoV, although the fatality rate of MERS-CoV was higher than SARS-CoV and 2019-nCoV. The major clinical manifestations in coronavirus infections 2019-nCoV, MERS-CoV, and SARS CoV are fever, chills. cough. shortness of breath, generalized myalgia, malaise, drowsy, diarrhea, confusion, dyspnea, and pneumonia. Global health authorities should take immediate measures to prevent the outbreaks of such emerging and reemerging pathogens across the globe to minimize the disease burden locally and globally.